Maharashtra Times, 9 June 2020:

Bharat Serums and Vaccines has received the Drug Controller General of India’s approval to undertake late stage Phase III clinical trials in Covid patients showing mild-to-moderate acute respiratory distress symptoms. Bharat Serums and Vaccines Ltd. (BSVL) is developing Ulinastatin as a potential treatment for COVID-19 patients with mild to moderate acute respiratory distress syndrome (ARDS).

Read more:

About BSV

BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases. For over four decades, BSVL has focused on utilizing its scientific resources to develop several biological, biotechnology and pharmaceutical products to treat various types of diseases, contributing to preserve, protect and enhance the quality of life. We aim to be a leading biopharmaceutical company driven by people & science to set benchmarks in patient outcomes in Women’s Health, Critical Care & Emergency Medicine.

For more information, please contact:

Irawati Gowariker, BSV, Irawati.gowariker@bsvgroup.com